大鼠便秘和巨结肠与钙拮抗剂奥索地平治疗有关。
Constipation and megacolon in rats related to treatment with oxodipine, a calcium antagonist.
作者信息
Nyska A, Waner T, Galiano A, Fich A
机构信息
Kimron Veterinary Institute, Beit Dagan, Israel.
出版信息
Toxicol Pathol. 1994 Nov-Dec;22(6):589-94. doi: 10.1177/019262339402200603.
The constipatory effects of oxodipine, a dihyrdopyridine-type calcium antagonist, have been described in a 3-mo, 12-mo, and 30-mo feeding toxicity study in rats. This paper reports the occurrence of megacolon in rats as a result of the constipatory effects of chronic administration of oxodipine. The first mortality due to oxodipine was seen after about 1 yr of treatment at a dose of 225 mg/kg/day. The toxic effects noted were dose-, time-, and sex-related. Female rats appeared more sensitive to the constipatory effects of the drug. The dose at which the effect occurred in both male and female rats was from about 75 to 675 times the recommended therapeutic dose for humans. To the best knowledge of the authors, this is the first report of a calcium channel blocker causing constipation in rats.
二氢吡啶类钙拮抗剂奥索地平的致便秘作用已在大鼠进行的为期3个月、12个月和30个月的喂养毒性研究中有所描述。本文报告了大鼠因长期服用奥索地平的致便秘作用而出现巨结肠的情况。在以225 mg/kg/天的剂量治疗约1年后，首次出现因奥索地平导致的死亡。观察到的毒性作用与剂量、时间和性别有关。雌性大鼠似乎对该药物的致便秘作用更为敏感。雄性和雌性大鼠出现该作用的剂量约为人类推荐治疗剂量的75至675倍。据作者所知，这是关于钙通道阻滞剂在大鼠中引起便秘的首次报告。
Zotero 插件